Global Vasculitis Treatment Market 2017-2021
- SKU ID : TNV-IRTNTR13490 10828971
- |
- Publishing Date: 21-Jun-2017
- |
- Region: Global
- |
- No. of pages: 78
About Vasculitis Treatment
Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. The body's immune system attacks the blood vessels, which results in inflammation. When this inflammation occurs, the walls of the affected blood vessels get thicker and the passages through which the blood flows get narrower, which reduces the amount of blood and oxygen delivered to vital organs.
Technavio’s analysts forecast the global vasculitis treatment market to grow at a CAGR of 4.20 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global vasculitis treatment market for 2017-2021. To calculate the market size, the report considers the sales from the drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Vasculitis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• CELGENE
• F. Hoffmann-La Roche
• GlaxoSmithKline
Other prominent vendors
• Ablynx
• AB SCIENCES
• Acorda Therapeutics
• Alder Biopharmaceuticals
• Antares Pharma
• Astellas Pharma
• AstraZeneca
• Baxter
• Boehringer Ingelhein
• Can-Fite BioPharma
• Celltrion
• ChemoCentryx
• Coherus BioSciences
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Gilead Sciences
• Hospira
• Idera
• Immunomedics
• ImmuPharma
• Incyte
• Invion
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• Merck
• MedImmune
• Morphotek
• Novo Nordisk
• Novartis
• Opexa Therapeutics
• Principia
• Regeneron
• Sandoz
• Sanofi
• Santarus
• Takeda
• UCB
• Vaccinex
• Vertex Pharmaceuticals
• Vitae Pharmaceuticals
Market driver
• Promising pipeline
• For a full, detailed list, view our report
Market challenge
• Loss of patent exclusivity of branded therapies
• For a full, detailed list, view our report
Market trend
• Strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. The body's immune system attacks the blood vessels, which results in inflammation. When this inflammation occurs, the walls of the affected blood vessels get thicker and the passages through which the blood flows get narrower, which reduces the amount of blood and oxygen delivered to vital organs.
Technavio’s analysts forecast the global vasculitis treatment market to grow at a CAGR of 4.20 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global vasculitis treatment market for 2017-2021. To calculate the market size, the report considers the sales from the drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Vasculitis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• CELGENE
• F. Hoffmann-La Roche
• GlaxoSmithKline
Other prominent vendors
• Ablynx
• AB SCIENCES
• Acorda Therapeutics
• Alder Biopharmaceuticals
• Antares Pharma
• Astellas Pharma
• AstraZeneca
• Baxter
• Boehringer Ingelhein
• Can-Fite BioPharma
• Celltrion
• ChemoCentryx
• Coherus BioSciences
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Gilead Sciences
• Hospira
• Idera
• Immunomedics
• ImmuPharma
• Incyte
• Invion
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• Merck
• MedImmune
• Morphotek
• Novo Nordisk
• Novartis
• Opexa Therapeutics
• Principia
• Regeneron
• Sandoz
• Sanofi
• Santarus
• Takeda
• UCB
• Vaccinex
• Vertex Pharmaceuticals
• Vitae Pharmaceuticals
Market driver
• Promising pipeline
• For a full, detailed list, view our report
Market challenge
• Loss of patent exclusivity of branded therapies
• For a full, detailed list, view our report
Market trend
• Strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
